1. Introduction {#s0005}
===============

Autism spectrum disorders (ASD) are a heterogeneous group of neurodevelopmental disorders that affect 1% of the population in developed countries and are characterized by persistent impairment in reciprocal social communication and restricted repetitive patterns of behavior ([@bb0140]). Challenges in developing efficient pharmacotherapies for ASD reside in the limited understanding of ASD etiology, the difficulties to experimentally model the disease, the heterogeneity of symptoms and the large variety of potential triggers. Nonetheless, in around a third of patients a genetic cause has been identified ([@bb0100]) and there appears to be a convergence on mechanisms controlling synaptic homeostasis and neuronal connectivity ([@bb0100], [@bb0175], [@bb0030]). Synapses and altered neuronal networks could be a relevant target to develop new therapeutic strategies for ASD ([@bb0170], [@bb0060]). Improved understanding of the molecular substrates of autism is raising the hope of innovative "disease-modifying" treatments for altering the course of the disorder.

However, while resulting in similar pattern core of symptoms, the synaptic/connectivity alterations in individuals with ASD show a considerable degree of heterogeneity, which may mask the potential beneficial effects of a tested treatment if it is not addressed properly to a subgroup of individuals stratified on the basis of the affected genes or pathways rather than on the clinical phenotype per se ([@bb0060]). This pleads for the design of new experimental and pre-clinical models to identify more personalized pharmacotherapies, approaches that require an access to relevant cellular models and tools that would allow analyzing at high throughput the effects of potential therapeutic compounds on human neurons.

In this light, we have previously shown that glutamatergic cortical neurons can be specifically differentiated from pluripotent stem cells (PSC) of either embryonic origin (human embryonic stem cells, hESC) or reprogrammed from somatic cells of patients with ASD caused by SHANK3 haplo-insufficiency (human induced pluripotent stem cells, hiPSC), and that they can serve as a cellular paradigm for high throughput screening (HTS) campaigns ([@bb0025]). Permitting the systematic comparison of hundreds of small molecules in parallel, this can therefore accelerate identification of therapeutic compounds targeting pathophysiological mechanisms underlying distinct forms of ASD. The goal of the present study was to verify such a strategy by focusing on S*HANK3* a key autism risk gene that codes for a synaptic scaffolding synaptic protein.

The synaptic protein SHANK3 has been linked to autism in different genetic screens where deleterious mutations affecting the *SHANK3* gene were present in 0.69 to 2.12% of individuals ([@bb0070], [@bb0105]). SHANK3 is an abundant component of the post-synaptic density (PSD) where it acts as a scaffolding protein recruiting key post-synaptic elements, such as glutamate receptors, and linking them to the actin cytoskeleton ([@bb0015]). This scaffolding role contributes to the formation, stabilization and strengthening of the glutamatergic synapses and increases the efficiency of the glutamatergic transmission ([@bb0085]). *SHANK3* Knock-Out mice recapitulate some key autistic behaviors and show reduced number and activity of glutamatergic synapses as well as loss in experience-linked plasticity ([@bb0150]). At the cellular level, neurons differentiated from iPSC derived from individuals with SHANK3 haploinsufficiency, exhibit impaired electrophysiological responses to glutamatergic synapse stimulations that can be corrected by re-introducing SHANK3 cDNA expression ([@bb0165]). Decreased glutamatergic neurotransmission thus appears as a central feature of SHANK3 haploinsufficiency and it can be reversed by restoring correct dosage of *SHANK3* even during adulthood ([@bb0175]). In individuals with ASD, *de novo* loss-of-function mutations of *SHANK3* reported in the literature affect only one allele of the gene, offering the opportunity to enhance transcription of the second allele, or improve mRNA stability and translation. We have therefore developed a high throughput molecular screening assay in order to pinpoint compounds increasing SHANK3 mRNA levels in human neurons derived from pluripotent stem cells.

2. Methods {#s0010}
==========

2.1. Human Pluripotent Stem Cells (hPSC) Origin {#s0015}
-----------------------------------------------

One hESC and 4 iPSC lines were used in this study. The male hESC line SA001 was obtained from Cellartis (Goteborg, Sweden). The work involving hESC line was supervised by the French Bioethics Agency (Agreement number NOR AFSB 12002 43S). The control iPSC line 1869 was published previously ([@bb0025]) and reprogrammed from fibroblasts obtained from the Coriell\'s biorepository (Coriell Institute for Medical Research, NJ, USA). The control line PB12 was reprogrammed from PBMC obtained from an anonymous blood donor at the French Blood Donor Organization. SHANK3-iPSC lines were derived from fibroblasts of 2 children with ASD carrying independent *de novo* SHANK-3 mutations. The 2 patients were diagnosed with autism and severe intellectual deficiency at the Robert Debré and Pitié-Salpétrière Hospitals according to DSM-IVTR criteria. Patient 1 (AUN-003, [@bb0105]) carries a *de novo* truncating mutation P.Glu809X in exon 21 and corresponds to iPSC line SHANK3-STOP. Patient 2 carries a frame shift mutation (c.3853_3857dup, p. Gly1287Alafs X15) and corresponds to the iPSC line SHANK3 frame-shift. Both were included initially in a national observational study (IDRCB 2008-A00019-46). After patient\'s legal representatives approval, 8-mm skin punch biopsies were obtained (study approval by Committee for the Protection of Persons, CPP no. C07-33). Fibroblasts were derived from the donated tissue and reprogrammed using the four human genes *OCT4*, *SOX2*, *c-Myc*, and *KLF4* cloned in Sendai viruses (Life Technologies, Carlsbad, CA, USA) and iPSC lines characterized according to [@bb0135]. The same procedure was used to reprogrammed and characterized control iPSC lines.

2.2. Derivation of Cortical Neural Stem Cells (NSC) from PSC {#s0020}
------------------------------------------------------------

Commitment of PSC to the neural lineage and derivation of stable cortical NSC was described previously ([@bb0020], [@bb0025]). Briefly, neural commitment was induced using the BMP inhibitor Noggin (500 ng/ml, Peprotech, London, UK) and the Nodal inhibitor SB431542 (20 μM, Tocris Biosciences, Ellisville, Missouri, USA). At day 10, neural rosettes containing neuro-epithelial cells were collected and plated *en bloc* in poly-[l]{.smallcaps}-ornithin/laminin treated culture dishes in N2B27 medium containing Epidermal Growth Factor (EGF, 10 ng/ml, Peprotech, Neuilly, France), FGF-2 (10 ng/ml, Peprotech) and Brain-derived Growth Factor (BDNF, 20 ng/ml, Peprotech). At confluence, the passages were performed using trypsin at a density of 50,000 cells/cm^2^. Mass amplification was performed until passage 8 and cells were frozen. To start the terminal differentiation as post-mitotic neurons, cortical NSC were dissociated and plated in N2B27 without growth factors.

2.3. Compound Library {#s0025}
---------------------

Two hundred and two small molecules were investigated, belonging to two commercially available libraries (Screen-Well® Kinase Inhibitor library, Enzo-life Sciences, 76 compounds and Screen-Well® Epigenetics library, Enzo-life Sciences, 43 compounds), I-stem laboratory reference compounds ([@bb0025], 50 compounds) and FDA approved drugs or related active principle (33 compounds). The complete list of compounds is provided in [Table S1](#ec0005){ref-type="supplementary-material"}.

2.4. Automated and High Throughput Quantification of SHANK3 mRNA in Human Neurons {#s0030}
---------------------------------------------------------------------------------

To start cortical neuron differentiation, NSC were dissociated and plated in N2B27 at a density of 6000 cells/wells in poly-[l]{.smallcaps}-ornithin/laminin pre-treated 384 well plates using the Bravo™ automated liquid handling platform equipped with a 384 pipette head (Agilent Technologies Inc., Santa-Clara, CA, USA). Half of the medium was changed twice a week. In those conditions, neuronal differentiation is achieved after 11 to 14 days. Kinetic of SHANK3 mRNA expression was established to determine the best time point to perform the screening ([Fig. S1](#f0040){ref-type="graphic"}) and day 14 was chosen since it offered the best dynamic range to quantify increase in SHANK3 mRNA expression. At day 14, compounds to be tested were added using the same platform in four replicates. The development and validation of the automated high throughput PCR assay by itself was performed following published standards for qPCR based HTS ([@bb0010]). mRNAs were extracted and directly converted in cDNA in the assay plate using the Fastlane technology (FastLane Cell Multiplex Kit, Qiagen, Courtaboeuf, France) with minor modifications. A duplex qPCR strategy was used, consisting in amplifying and quantifying both *SHANK3* and the house keeping gene *PeptidylProlyl Isomerase A* (PPIA) in the same well (QuantiFast Probe Assay DP Kit). The robustness of this method was evaluated by performing it in 66 technical replicates. Ct values were consistent between technical replicates with minimal inter-well variations ([Fig. S1](#f0040){ref-type="graphic"}). In order to evaluate the sensitivity of the duplex TaqMan PCR to *SHANK3* mRNA level modifications, *SHANK3* specific shRNAs were used to artificially decrease the level of transcripts in PSC-derived neurons. Sister neuronal cultures were nucleofected (Amaxa, Lonza, Amboise, France) with non-targeting shRNAs as controls. The performance of the simplex method was compared with the automated duplex Taqman qPCR strategy and both strategies found equally efficient, indicating than automation and multiplexing had not compromised the sensitivity and specificity of the assay ([Fig. S1](#f0040){ref-type="graphic"}). Finally, the dynamics of *SHANK3* mRNA synthesis was analyzed in order to estimate a relevant duration of treatment with the tested compounds. Neurons were treated with 5,6-dichloro-1-beta-[d]{.smallcaps}-ribofuranosylbenzimidazole (DRB) during 48 h to block mRNA production ([Fig. S1](#f0040){ref-type="graphic"} [@bb0160]). Treatment with 100 μM of DRB decreased SHANK3 mRNA content by 63%. After 24 h of release from DRB, SHANK3 mRNA contents were partially reconstituted and reached 80% of the non-treated cells. Neurons were, therefore, treated over 24 h for drug screening. The final screening workflow is summarized in [Fig. 1](#f0005){ref-type="fig"}a. Fold change variations induced by compound treatments were calculated using the 2ΔCt method with DMSO-treated cells as controls and PPIA as the reference gene.

2.5. Automated Image-based High Content Screening {#s0035}
-------------------------------------------------

For high-content screening assays, cells were fixed in 4% paraformaldehyde for 15 min at 4 °C. Primary antibodies ([Table S2](#ec0010){ref-type="supplementary-material"}) diluted in blocking buffer were applied overnight at 4 °C. Hoechst 33,258 (2 μg/ml, Sigma) and secondary antibodies conjugated to Alexa fluorophores (Molecular Probes, Eugene, Oregon, United States) were diluted at 1:1000 in blocking buffer and applied for 2 h at room temperature. To quantify synapses, image acquisition and analyses were performed using the ImageXpress® Micro XLS system (Molecular Devices, Sunnyvale, CA, USA). A presynaptic marker and a postsynaptic marker were used and multiplexed with the neuronal markers HuC/D and beta III Tubulin (anti-Tuj-1 antibodies) to identify neurons and create a "neurite" mask. An algorithm was then generated using MetaXpress™ software application modules in order to identify pre- and post-synaptic spots specifically located on neurites, then to count the number of spot co-localization (considered as synapses). Results were expressed as the density of spots for 100 μm of neurite. A minimum of 10 sites per well (approximately 2000 neurons) was analyzed. For neuritic network parameter analysis, image acquisition was performed using Cellomics Arrayscan system (Thermofischer Scientific, Waltham, MA, USA). Beta-III tubulin staining was used to track neurite using "Neuronal profiling" bioapplication as described in ([@bb0025]).

2.6. Spontaneous Calcium Oscillation Recording {#s0040}
----------------------------------------------

After 35 to 42 days of differentiation, neurons were treated during 120 h with compounds of interest in 384 well-plates. Cells were incubated for 10 min at 37 °C with the Fluo-4 probe diluted at 1 mM in a loading buffer (HBSS 1X, Hepes Buffer 20 mM, pH 7.4). After 3 washes with Mg^2 +^-free Buffer (HBSS w/o CaCl2, w/o MgCl2, Hepes Buffer 20 mM, CaCl2 2 mM, pH = 7.4), neurons were recorded in the Mg^2 +^-free Buffer. The fluorescence reading was performed with the ImageXpress® Micro XLS System at 37 °C. Neurons were recorded every second during 3 min with an exposure time of 350 ms. Total fluorescence curves were extrapolated using MetaXpress software.

2.7. Transcriptome Analysis {#s0045}
---------------------------

For transcriptome analysis of gene expression perturbations induced by lithium and VPA, human neurons differentiated from the SA001 line were treated during 24 h with compounds and RNA extracted using RNAeasy extraction kit following manufacturer\'s instructions (Qiagen). Fifty ng of total RNA was reverse transcribed using the Ion AmpliSeq Transcriptome Human Gene Expression kit (Revision A.0) following the protocol of the manufacturer (Thermo Fisher Scientific). The cDNA libraries were amplified and barcoded using Ion AmpliSeq Transcriptome Human Gene Expression core panel and Ion Xpress Barcode Adapter (Thermo Fisher Scientific). The amplicons were quantified using Agilent High Sensitivity DNA kit before the samples were pooled in sets of eight. Emulsion PCR and Enrichment and loading was performed on the Ion Chef Instrument using the Ion PI IC 200 Kit (Thermo Fisher Scientific). Samples were loaded on an Ion PI v3 Chip and sequenced on the Ion Proton System using Ion PI IC Hi-Q 200 Kit chemistry (200 bp read length Thermo Fisher Scientific). The output files (FASTQ files) were imported into the RNA-seq pipeline of Partek Flow software (v 4.0, Partek Inc., St Louis, MO, USA) using hg19 as a reference genome. To determine genes that are differentially expressed between groups mapped reads were quantified using Partek E/M algorithm (the resulting counts represent the gene expression levels for over 20,800 different genes present in the AmpliSeq Human Gene Expression panel) and differentially expressed gene were identified using Partek Gene Specific Analysis (GSA) algorithm. Biological interpretations of the list of differentially expressed genes were performed using Partek Flow v4.0 and the pathway analysis plateform EnrichR ([@bb0055]).

2.8. Statistical Analyses {#s0050}
-------------------------

Data were subjected to ANOVA following by a *t*-test to evaluate statistical differences between cells treated with tested compounds and DMSO-treated controls. The number of biological replicates, corresponding to independent differentiations or neuronal cultures, is indicated in figure legends.

3. Results {#s0055}
==========

3.1. Screening of Compounds Regulating *SHANK3* mRNA Expression in Human Neurons Differentiated from hESC {#s0060}
---------------------------------------------------------------------------------------------------------

A collection of 202 compounds was chosen for the primary screening of *SHANK3* regulators. This collection included a set of FDA-approved therapeutic compounds widely used for a variety of psychiatric and neurological diseases including epilepsy, bipolar disorders, major depressive disorders or schizophrenia. It also included epigenetic regulators, kinase inhibitors and compounds identified previously as modulators of neurogenesis ([@bb0025]) ([Table S1](#ec0005){ref-type="supplementary-material"}). Reprogramming of somatic cells into iPSC being potentially responsible for induction of epigenetic and imprinting alterations that could bias the study of gene regulation ([@bb0155], [@bb0180], [@bb0115]), the primary drug screening was conducted using neurons differentiated from the control hESC line SA001. The 202 compounds were screened in 4 biological replicates at one concentration determined for each compound based on data from the literature or from our own previous findings ([@bb0025], [@bb0075]). This primary drug screening identified 29 primary hits that increased *SHANK3* mRNA content by at least 30% as compared to DMSO-treated cells and with a deviation from the DMSO mean of more than 2 σ ([Fig. 1](#f0005){ref-type="fig"}b and [Table S1](#ec0005){ref-type="supplementary-material"}). Re-testing of these 29 hits in an independent experiment confirmed 22 compounds ([Fig. 1](#f0005){ref-type="fig"}b). Dose-response experiments were then conducted and revealed a concentration-dependent mode of action for 15 of them ([Fig. 1](#f0005){ref-type="fig"}b and c). Among this list of 15 compounds, 6 were chosen to be further investigated: 5 FDA-approved compounds (fendiline dihydrochloride, lithium, valproic acid, aripiprazol and fluoxetine) and the 5-lipoxygenase inhibitor BWB-70C since it regulated a pathway that can be targeted by the FDA-approved compound Zileuton. The optimal concentrations for each pharmacological compound were determined from the mRNA dose-response curves, and defined as follows: lithium 0.5 mM, valproic acid (VPA) 2 mM, aripiprazol 7.5 μM, fluoxetine 10 μM, fendiline 5 μM, BWB70C 40 μM ([Fig. S2](#f0045){ref-type="graphic"}).

3.2. Modification of SHANK3 Synaptic Content and Neuronal Activity by Hit Compounds {#s0065}
-----------------------------------------------------------------------------------

The functional potential of the six drugs was first evaluated in neurons derived from the SA001 hESC line. SHANK3 protein levels and its recruitment to the glutamatergic synapses, as well as increased glutamatergic activity of neuronal network were used as indicators of compound efficacy. The time course of synaptogenesis was analyzed by quantifying the number of spots of the pre-synaptic protein Synapsin and of the post-synaptic density component PSD-95 present on neurites, a co-localization suggesting a glutamatergic synapse ([Fig. 2](#f0010){ref-type="fig"}a). In untreated hESC-derived neuronal cultures, expression of Synapsin and PSD-95 in the neuritic compartment progressively increased from day 14 to 28 and synapses were clearly present at day 28. The effects of the 6 compounds on SHANK3 synaptic content was therefore analyzed at that later stage. In order to optimally quantify SHANK3 protein production following treatment, cells were exposed to compounds for at least 120 h.

Only 3 out of the 6 compounds increased SHANK3 at the protein level in neurons at the tested concentrations, namely lithium, VPA, and fluoxetine ([Fig. 2](#f0010){ref-type="fig"}b). The same 3 compounds also significantly increased the number of neuritic sites in which SHANK3 co-localized with PSD-95 ([Fig. 2](#f0010){ref-type="fig"}c and d; [Fig. S3](#f0050){ref-type="graphic"}), suggesting an efficient recruitment at the post-synaptic density. Treatment with lithium and VPA, but not fluoxetine, increased the co-localization of SHANK3 with the presynaptic marker Synapsin, taken as the indication of SHANK3 containing synapses ([Fig. 2](#f0010){ref-type="fig"}c and d).

The relationship between the increased number of SHANK3-containing synapses and functional changes in the neuronal network connectivity was then investigated. At day 37, neurons were treated with lithium, VPA or fluoxetine during 5 days, then network spontaneous calcium oscillations (SCO), reflecting the number of mature synapses ([@bb0065], [@bb0045]), were measured using Fluo-4 calcium probe ([Fig. 3](#f0015){ref-type="fig"}). Lithium and VPA, but not fluoxetine, increased both SCOs frequency and intensity in treated cortical neurons in a statistically significant manner indicating increased network connectivity. This effect was strongly decreased (VPA) or totally lost (lithium) in neurons in which shRNAs targeting SHANK3 were expressed, confirming that the effects of the drugs were dependent on SHANK3 ([Fig. 3](#f0015){ref-type="fig"}).

3.3. mRNA Profiling Following VPA and Lithium Treatments {#s0070}
--------------------------------------------------------

In order to document more generally the effect of lithium and VPA on synaptic mRNAs, expression profile of 150 neuronal and synaptic genes was established after treatment of SA001-derived neurons by lithium or VPA ([Fig. 4](#f0020){ref-type="fig"}a and [Table S3](#ec0015){ref-type="supplementary-material"}). Lithium exerted a discrete effect with only 16 genes up-regulated in the same range as *SHANK3*, i.e. with a fold change compared to DMSO of more than 1.4, none of them being up-regulated more than 3 fold. Among these 16 genes, 6 were direct or indirect partners of SHANK3 at the synapse, namely, the PSD protein HOMER2, the metabotropic glutamate receptors GRM1, GRM3 and GRM6, the NMDA receptor sub-unit NR4A1 and the metalloprotease MMP-9. The 10 additional genes were neurotrophins (*NTF3* and *NTF4*), GABA transporters (*SLC6A12* and *SLC6A13*), one purinergic receptor (*P2RX7*), interleukin *IL1B*, arginine vasopressin *AVP*, NO synthase *NOS-1* and two protein kinases (*PRKG1* and *PRKCG*). In contrast, VPA profoundly modified synaptic mRNAs content with more than 60% of the genes being up-regulated above 1.5 fold as compared to DMSO, and up to 34 fold changes. This discrete effect of lithium on gene expression was further confirmed by global transcriptomic analysis. Whole genome RNA sequencing revealed that only 331 genes were modified by lithium treatment in SA001 neurons (Fold change \>+1.5 or − 1.5 compared to DMSO treated neurons, *p* \< 0.05). In contrast, VPA treatment induced the dysregulation of 2161 genes in the same range ([Fig. 4](#f0020){ref-type="fig"}b, c and [Table S4](#ec0020){ref-type="supplementary-material"}).

3.4. Up-regulation of SHANK3 mRNA is dependent of HDAC inhibition but independent on GSK-3 inhibition {#s0075}
-----------------------------------------------------------------------------------------------------

Candidate signaling pathways potentially linking VPA and lithium to SHANK3 up-regulation were further investigated. The way each one of these pharmacological agent exerts its therapeutic activity on neuronal cells is not fully understood since both are suggested to inhibit a large variety of enzyme-dependent cascades ([@bb0080]). We therefor decided to investigate commonly targeted signaling pathways. Lithium and VPA are considered as two mood stabilizers sharing at least two important common cellular targets: the Glycogen Synthase Kinases of type 3 (GSK-3) and class I Histone Deacetylases (HDAC) ([@bb0195], [@bb0110], [@bb0050]). Involvement of these two pathways in SHANK3 mRNA regulation was investigated by treating SA001-derived neurons using Trichostatin A, a potent and selective HDAC inhibitor, or CHIR99021 a selective GSK-3 inhibitor ([Fig. 4](#f0020){ref-type="fig"}d). After 24 h of treatment, Trichostatin A significantly increased SHANK3 mRNA. In contrast, CHIR99021 was not able to mimic the effect of lithium and VPA on SHANK3 mRNA. In parallel, RNA sequencing data indicated that lithium and VPA commonly up-regulated 12 genes while down-regulating 149 ([Fig. 4](#f0020){ref-type="fig"}c, [Table S4](#ec0020){ref-type="supplementary-material"}). This list of gene was further investigated using the pathway enrichment analysis tool PANTHER (Protein ANalysis THrough Evolutionary Relationships) via EnrichR. Commonly regulated genes did not cluster into signaling pathways linked to GSK-3 or any metabolic enzymes directly targeted by lithium or VPA. In contrast, among the 149 down-regulated genes, 5 histone isoforms were identified (HIST1H1B, HIST1H1C, HIST1H2B, HIST1H4A, HIST1H4D, [Table S4](#ec0020){ref-type="supplementary-material"}). Together, this suggested that lithium and VPA-mediated increase of SHANK3 mRNA levels could be triggered via an epigenetic mechanism involving histone regulation.

3.5. Lithium and VPA Action on Neurons Differentiated from iPSC of Patients with *SHANK3* Mutations {#s0080}
---------------------------------------------------------------------------------------------------

To evaluate compounds efficacy on SHANK3 haplotypes associated phenotypes, iPSC lines were derived from two children with autism and severe intellectual disabilities who carried two different deleterious mutations in one allele of *SHANK3* (SHANK3-STOP and SHANK3 frame-shift, [Fig. S4](#f0055){ref-type="graphic"} and [@bb0105]). The two mutations were predicted to lead to loss of function of one of the two alleles of *SHANK3*, leaving one functional allele. Neurons were first differentiated and compared to neuronal cultures differentiated from two control lines PB12 and 1869 ([Fig. 5](#f0025){ref-type="fig"} and [Fig. S4](#f0055){ref-type="graphic"}). As described previously, SHANK3 haplo-insufficiency did not significantly influence the rate of neuronal differentiation as determined by quantifying the fraction of the cells expressing the neuronal specific proteins HuC/D ([Fig. S4](#f0055){ref-type="graphic"}) or NeuN ([Fig. 5](#f0025){ref-type="fig"}a and e) and Tuj-1 ([Fig. 5](#f0025){ref-type="fig"}e). After 28 days of differentiation, all the culture contained more than 70% of post-mitotic neurons independently of the presence or absence of SHANK3 haplo-insufficiency. In parallel, the fraction of dividing neuronal precursors, characterized by the co-expression of Sox2 and Ki67 were lower than 10% ([Fig. S4](#f0055){ref-type="graphic"}). SHANK3 haplo-insufficiency did not modify the type of neurons produced that were mostly glutamatergic neurons, expressing vGlut-1/2 ([Fig. 5](#f0025){ref-type="fig"}b and f), of the superficial cortical layers (expressing the layer specific marker Cux1, [Fig. 5](#f0025){ref-type="fig"}b and [Fig. S4](#f0055){ref-type="graphic"}, [@bb0025], [@bb0200]). Neuronal phenotypes previously associated with SHANK3 loss of function were then deeply analyzed to determine whether they were robustly recapitulated in neurons differentiated from iPSC of patients with disruptive point mutation in SHANK3 gene. Neuritic network morphology was analyzed by automatically tracking neurite using beta-III tubulin staining (anti-Tuj-1 antibodies, [Fig. 5](#f0025){ref-type="fig"}c and e). Analysis of two different neuritic network parameters, i.e. the size of the neuritic network associated with a single neuron (neurite length by neuron) and the way this neuritic network develop complexity (branching point number per neuron) indicated that SHANK3 haplo-insufficiency impacted significantly neurite branching ([Fig. 5](#f0025){ref-type="fig"}c and e). Quantification of the density of SHANK3 spots on neurites confirmed that SHANK3 haploinsufficiency was associated with lower SHANK3 expression at synaptic sites since the density was significantly lower in the neuronal cultures differentiated from the two SHANK3 mutated iPSC lines ([Fig. 5](#f0025){ref-type="fig"}d, g). Together, this led to deficient neuronal connectivity as revealed by decreased intensities and frequencies of SCOs recorded in the two patient-derived neuronal cultures after 42 days of differentiation ([Fig. 5](#f0025){ref-type="fig"}h, i).

The recapitulation of SHANK3 deficiency associated phenotypes in neurons of patients with disruptive point mutations allowed us to use them as a biological support to test the efficiency of VPA and lithium. Neurons with SHANK3 mutations were treated with VPA or lithium during 120 h. The two drugs had only a slight effect on neurite branching ([Fig. 6](#f0030){ref-type="fig"}a) but significantly increased the number of SHANK3-containing synapses ([Fig. 6](#f0030){ref-type="fig"}b, d) as well as SCOs frequency and intensity in the two SHANK3 genetic backgrounds ([Fig. 6](#f0030){ref-type="fig"}c, e). This suggested that these two compounds may be of beneficial for patients from whom the iPSC were derived.

3.6. Clinical Assessment of Lithium Treatment on ASD Severity in a SHANK3-STOP Patient {#s0085}
--------------------------------------------------------------------------------------

Patient AUN-003, from whom the iPSC line SHANK3-STOP was derived (*de novo* truncating mutation P.Glu809X) was enrolled in 2012, aged 12 years old, in an observational clinical study ([Fig. 7](#f0035){ref-type="fig"}, T0). She had a severe ASD measured with the Social Responsiveness Scale (SRS, raw score = 101, t-score = 89), the Autism Diagnosis Observational Scale (ADOS, social affect domain raw score = 23) and the Autism Diagnosis Interview-Revised version (data not shown). She displayed a mild intellectual disability with contrasting results on the Peabody Picture Vocabulary Test (PPVT) (t-score: 101) and the Raven\'s progressive matrices (RPM) (raw score = 9, t-score: \< 65). However, her adaptive behavior was below her cognitive ability based on the Vineland\'s module 2 (communication domain raw score = 41) or the Global Assessment Scale (GAS, raw score = 30). At T0, by screening her psychiatric comorbidity with the Kiddie SADS, a semi-structured interview, patient AUN-003 had no lifetime history of Attention Deficit Hyperactive Disorder (ADHD) or of bipolar affective disorders (including manic symptoms). Seven months later ([Fig. 7](#f0035){ref-type="fig"}, black arrow), she developed symptoms of mood deregulation. During several months, she displayed major depressive symptoms followed by a hypomanic episode with mixed features. The maximum intensity of manic symptoms was retrospectively assessed with the Young-Mania rating Scale (Y-MRS, raw score = 26). Five months later, ([Fig. 7](#f0035){ref-type="fig"}, red arrow), facing inability to control the symptoms, lithium was introduced as an indication for bipolarity. Considering the *in vitro* results obtained on her iPSC derived neurons, ASD scores were carefully assessed. After 8 months of treatment (T1), she displayed a clear improvement on manic symptoms (Y-MRS raw score = 18). In addition, a modest but significant positive effect was identified on ASD severity, as evaluated by the SRS (raw score = 84, t-score = 80), as well as on her cognitive performance measured with the RPM (raw score = 13, t-score \< 70). However, the adaptive behavior was not improved whatever the scale considered (GAS = 25, Vineland communication domain score = 31). After one year (T2) adaptive behavior started to improve as compared to T1, though still close to the performance at T0 (GAS = 30, Vineland score = 35), i.e. before regression. In contrast, the caregivers reported additional reduction of autistic symptoms on the SRS (raw score = 73, t-score = 75), which was further confirmed by results on the ADOS (social affect domain raw score = 17). These two tests revealed that ASD symptoms were lower than before regression. In contrast, there has been a degradation of her ability to control her impulsivity between T1 and T2, associated to distractibility. Caregivers mentioned that these symptoms differed from those observed during the manic episodes. Despite their late onset, symptoms tended to evoke clinical features of ADHD (ADHD-RS, global raw score = 25). [Table S5](#ec0025){ref-type="supplementary-material"} reports in details the scores obtained for each tests and each sub-categories.

4. Discussion {#s0090}
=============

*SHANK3* haplo-insufficiency induced by heterozygous loss of function mutations represents a clear model of abnormal gene dosage leading to ASD ([@bb0070], [@bb0200]) that can be reversed by genetically re-introducing SHANK3 normal levels of expression, including during adulthood, in mice models ([@bb0165]). ([@bb0125]). We therefore proposed that successful therapeutic compounds for SHANK3 haplo-insufficiency dependent form of ASD could be identified based on their potential to up-regulate this gene in human neurons. We first selected potential hit compounds using control hESC derived neurons, to avoid epigenetic bias potentially induced by iPSC reprogramming ([@bb0180], [@bb0115]). Patient-derived iPSC cellular models were then used to challenge their efficacy at corrected SHANK3-associated neuronal phenotypes considered as relevant for ASD symptoms ([@bb0035], [@bb0200]). Interestingly, among the compounds regulating SHANK3 identified in the present study were the two mood stabilizers VPA and lithium that share common cellular targets. Additionally, we reported promising results of lithium pharmacotherapy to reduce ASD core symptoms in one of the patient from whom iPSC were produced. Supporting our observations, lithium was previously shown to overcome neonatal isolation-induced autistic-like behavior in a rat model by restoring the compromised balance between excitatory/inhibitory synaptic activities ([@bb0190]). Lithium was also proposed as a potential therapeutic approach for Fragile X syndrome. Chronic lithium treatment contributes to normalized behavior and synaptic transmission in mice models of Fragile X syndrome and pilot clinical trials have shown promising results in individuals with Fragile X syndrome ([@bb0120]). This suggests that lithium may have a global positive effect on glutamatergic synapse genesis and homeostasis. This would be consistent with mRNA profiling performed in the present study, which indicate that lithium positively regulates SHANK3 together with 6 of its protein-partners at the glutamatergic synapse. How lithium regulates *SHANK3* remains, however, to be fully characterized as lithium acts on a large variety of signaling pathways ([@bb0195], [@bb0145], [@bb0130]). Our results suggest that lithium, as VPA, may act, in part, through its HDAC inhibitory activity and regulate SHANK3 via an epigenetic mechanism. Lithium was demonstrated to inhibit inositol dependent enzymes by depleting inositol cellular content ([@bb0080]). Interestingly, HDAC were recently demonstrated as depending of inositol for proper activity ([@bb0185]). This suggests that Lithium may directly inhibit HDAC activity via inositol depletion. In addition, we found that Lithium, as VPA, down-regulated directly histone expression. Together, lithium and VPA may regulate SHANK3 at an epigenetic levels via several pathways linked to histone linkage to DNA. Clinical assessment of patient AUN-003 suggested that lithium, initially provided for bipolar disorders, improved also her social and interaction behavior as evaluated using SRS and ADOS. Interestingly, after one year of treatment, performances on SRS and ADOS were better than when she was first enrolled in the study 2.5 years before (T0), i.e. before the beginning of mood deregulation. These effects on scales exploring ASD were not correlated with performance on global adaptation behavior scales (Vineland and GAS), suggesting that the improvement recorded for ASD symptoms was not, at least not only due to a recovery from regression or a placebo effect. While encouraging, our case report also revealed the emergence of ADHD in this patient that should serve as a cautionary tale for the premature use of this approved medication for a complex condition such as ASD. These symptoms resembled the hyperkinetic, manic-like, disorders described previously in two patients with SHANK3 duplication and mimicked in *SHANK3* overexpressing mice([@bb0090]). In this mouse model, lithium was inefficient at correcting SHANK3 dependent maniac-like behavior, in contrast to VPA, an atypical pharmacological profile for manic-like disorders. In light of our results, the up-regulation of *SHANK3* by lithium may explain the lack of efficacy. Regarding VPA, additional action of this compound on the GABAergic system may overall result in a correction of the manic-like behavior despite up-regulating *SHANK3*. Collectively, this suggests that lithium may have improved ASD symptoms but induced ADHD-like behavior by increasing SHANK3 in AUN-003. These observations highlight the fact that proper *SHANK3* dosage is critical for normal brain function, and warrant deeper investigation of the mechanisms of action of lithium, VPA and related agents and their potential benefits for patients with *SHANK3* haplo-insufficiency. Our work pleads for a deeper characterization of instrumental pathways sustaining lithium action on SHANK3 to identify more specific molecules and avoid potential non-desired side effects resulting from the inhibition of multiple cellular targets not involved in SHANK3 regulation. Additionally, animal testing will be critical to elucidate lithium efficacy. So far, the most widely studied models are mice fully knock-out for SHANK3 isoforms. These mice exhibit strong and robust abnormal behavior (review in [@bb0095]). Consistently, validation of pharmacological approaches preferentially uses these KO mice ([@bb0040], [@bb0005]). However, our approach is based upon the identification of compounds rescuing SHANK3 associated phenotypes by increasing SHANK3 mRNA levels. Testing of lithium would therefore need to be performed in heterozygous mice with one wild-type allele. Unfortunately, these mice develop only very specific and discrete phenotypes ([@bb0035]), the robustness of which limiting their use as model for testing efficiency of pharmacological approaches. Finally, formal conclusions would come from a randomized double blind clinical trial against placebo that will be needed to accurately validate the effect of lithium in patients carrying SHANK3 loss of function mutations and exclude any possibility of symptom improvement solely due to change in educational care or any other environmental factors.

5. Conclusion {#s0095}
=============

The main result of this study is the demonstration that lithium, the FDA-approved drug for bipolar disorders, regulates *SHANK3* expression in a way that bears therapeutic potential for patients with ASD associated to *SHANK3* haploinsufficiency. This result has been obtained on the basis of a drug screening challenging molecular and functional phenotypes relevant to the disease in neurons derived from pluripotent stem cell lines, including from patients awaiting a treatment. This novel methodology for drug discovery is applicable to other forms of ASD with contrasting pathophysiological substrates, as well as to other CNS disorders with known molecular anomalies. As such, it offers an avenue to the stratification of treatment and, ultimately, personalized medicine for psychiatric disorders.

The following are the supplementary data related to this article.Fig. S1SHANK-3 screening assay developmenta) Quantification of SHANK-3 mRNA in hESC-derived differentiating neurons using manual mRNA extraction and SYBR green detection techniques. b) Expression of SHANK-3 protein in neurons at day 14. Scale bar = 200 μm c) Mean Ct values and standard deviations of SHANK-3 and PPIA detection using Duplex Taqman method evaluated in 66 technical replicates of DMSO treated neurons. ΔCt corresponds to Ct PPIA-Ct SHANK-3. d) Comparison of the sensitivity of the manual RNA extraction following by simplex SYBR green detection method with the automated RNA extraction combined with TaqMan duplex detection method using neurons transfected with control or SHANK-3 specific shRNAs. Results represent mean ± SD of 4 independent biological replicates. \* *p* \< 0.001 *t*-test. e) Determination of SHANK-3 mRNA turn over using the mRNA synthesis inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB). Results represent mean ± SD of 3 independent biological replicates. \* *p* \< 0.001 *t*-test.Fig. S1Fig. S2Concentration -- response curves of the 6 chosen compounds.Results are expressed as Fold-change compared to DMSO-treated cells and presented as mean ± SD of 3 independent replicates.Fig. S2Fig. S3Expression of SHANK-3 in hESC derived neurons.Representative images of SHANK-3 co-localisation with the neuritic marker Tuj-1 and the post-synaptic protein PSD-95. Scale bar = 50 μm.Fig. S3Fig. S4Additional characterization of iPSC-derived neurons and response to lithium and VPA treatments.a) Schematic representation of SHANK3 protein domains and description of the two SHANK3 mutations identified in the ASD children from whom iPSC were derived. b) Pedigrees of the family of patient ASD03 (SHANK3 frameshift). The chromatograms were obtained after Sanger sequencing. The arrow indicates the frame-shift. c) Quantification of neurogenesis, in control (1869 and PB12) and SHANK3 mutated (SHANK3 STOP and SHANK3 frame shift) lines. Post-mitotic neurons were quantified using the neuronal specific nucleo-protein HuC/D whereas SOX2/ki67 double positive cells represent cycling neuronal precursors. Results represent mean ± SD of at least 2 independent differentiations. d) Representative expression of HuC/D, Ki67 and Cux1 in 28 days neuronal cultures from the two control lines PB12 and 1869 and from the two SHANK3 mutated lines. Scale bars = 50 μm.Fig. S4Table S1Primary screening resultsList of tested compounds and their concentration used in the primary screening as well as SHANK3 fold changes compared to DMSO treated cells. Results are provided as mean ± SD of 4 replicates (independently treated neuronal cultures).Table S1Table S2List of antibodies used in this studyName, host species, working concentrations and providers of the primary antibodies used in this study.Table S2Table S3mRNA profiling of neuronal and synaptic gene following lithium and VPA treatmentResults of fold change expression of treated cells vs DMSO for all the genes present in the two mRNA profiling assays, namely the "synaptic protein" and the "GABA Glutamate" arrays. Results are provided as mean ± SD of 3 replicates (independently treated neuronal cultures).Table S3Table S4Transcriptomic analysis following lithium and VPA treatmentLists of gene modified in 14 days human neurons following treatment with VPA or lithium. Results are expressed as mean fold change of 3 independently treated neuronal cultures compared to DMSO treated cultures. The lists were established using the following threshold: *p* value \< 0.05 (GSA algorithm, Partek Inc.), Fold change \> 1.5 or − 1.5 compared to DMSO. Pathway analyses were performed using Panther algorithm via the open access EnrichR on line platform.Table S4Table S5Complete clinical assessment of patient AUN-003Assessment scores obtained while exploring the patient AUN-003. SRS: Social Responsiveness Scale, ADOS: Autism Diagnosis Observational Scale, PPVT: Peabody Picture Vocabulary Test, RPM: Raven\'s progressive matrices, GAS: Global Assessment Scale, Y-MRS: Young-Mania rating Scale, ADHD: Attention Deficit Hyperactive Disorder rating scale.Table S5
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![SHANK3 screening results.\
a) Screening work flow. b) Screening success rate. Among 202 molecules, 29 primary hits (increase of at least 30% of expression of the DMSO-treated wells which correspond to a statistical deviation of more than 2 σ) were identified. Independent re-testing confirmed 22 compounds. Dose response experiments revealed a concentration-dependent mode of action for 15 compounds. Among this list of 15 compounds, 6 were chosen for further investigation. c) Table summarizing the name of the 15 compounds demonstrating a dose-dependent effect on up-regulating SHANK3 mRNA, their known biological target or medical application and their performance in the primary screening. Results are presented as the mean fold-change values compared to DMSO treated cells and standard deviations (SD) of the 4 biological replicates. The 6 compounds chosen for further investigation are in red.](gr1){#f0005}

![Effect of hit compounds on SHANK3 protein expression and synaptic location.\
a) Time course analysis of synapse formation in hESC-derived developing neurons. Results are expressed as mean ± SD of 3 independent neuronal cultures (biological replicates, left panel). Representative images of the pre-synaptic marker Synapsin (green) and the post-synaptic marker PSD-95 (red) are shown on the right panels. Arrow indicates example of co-localization of PSD-95 and Synapsin signaling structural synapses. b) Quantification of SHANK3 protein expression on dendrites after treatment with hit compounds. Results are expressed as mean ± SD of 6--8 independent neuronal culture/ treatment (biological replicates) and as fold change compared to DMSO-treated cells. \* *p* \< 0.01 *t*-test c) Quantification of SHANK3 protein co-localization with synapsin and PSD-95 after compound treatment. Results are expressed as fold change of DMSO treated cells (mean ± SD, 6--8 biological replicates par treatment). d) Representative image of SHANK3 (green) co-localization with synapsin (red). Scale bar = 50 μm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr2){#f0010}

![Functional analysis of neuronal network activity following compounds treatment.\
a--b) Quantification of spontaneous calcium oscillations (SCO) frequency (spikes/min, a) and intensity (FAU: Fluorescence Arbitrary Units, b) in neurons treated with DMSO, fluoxetine, lithium and valproic acid (VPA). SCO were recorded over a period of 180 s, results represent mean ± SD of 5--6 biological replicates/treatment. \**p* \< 0.01 *t*-test compared to DMSO treated cells. shRNA: neurons stably expressing a cDNA coding for a SHANK3 shRNA c) Representative example of recordings.](gr3){#f0015}

![Molecular targets of VPA and Lithium in human neurons.\
a) Heat map of gene expression profiles of 150 genes involved in synaptic plasticity or GABA/glutamate pathways in DMSO (column 1), lithium (column 2) or valproic acid (VPA, column 3) treated neurons. FC: Fold change of mRNA expression when compared to DMSO-treated cells. b) Volcano plots showing the distribution of differentially expressed genes in neuronal cultures treated with Lithium or VPA compared to DMSO (*p* value GSA test \< 0.05). Results represent mean of 3 independent neuronal cultures per treatment. c) Venn\'s Diagram illustrating genes independently or commonly targeted by lithium and VPA treatments. d) Effect of inhibitors of GSK-3 (CHIR 99021) and HDAC (Trichostatin A) dependent pathways on *SHANK3* mRNA expression. SHANK3 mRNA levels were quantified 24 h after treatment with 5 or 10 μM of the indicated inhibitor. PPIA was used as a reference gene. Results are expressed as fold change compared to DMSO treatment (0 μM) and represent mean ± SD of 4 independent neuronal cultures per treatment. \* *p* \< 0.05.](gr4){#f0020}

![Neurons differentiated from patients with SHANK3 mutations recapitulate cellular phenotypes associated to SHANK3 haploinsufficiency.\
a) Quantification of the number of neurons (NeuN/Tuj-1 double positive cells) per field of 330 μm2, in control (1869 and PB12) and SHANK3 mutated (SHANK3 STOP and SHANK3 frame shift) lines. Results represent mean ± SD of at least 6 independent differentiations, with a minimum 10 fields per culture. b) Quantification of neuronal sub-type present in 28 days neuronal culture obtained from controls or SHANK3 cells. vGlut1/2 expression indicated glutamatergic neurons and Cux-1 expression marked cortical glutamatergic neurons of the superficial layers. Results are mean ± SD of 3 independent differentiations. c) Quantification of neuritic network parameters in control (iPSC 1869 and iPSC PB12) and SHANK3 mutated (SHANK3-STOP and SHANK3 frame shift) 28 days-old neuronal cultures. Neurite total length represents the size in μm of the neuritic network associated with one neuron while the number of branching points quantifies more specifically neurite network complexity. Results represent mean ± SD of at least 6 independent neuronal cultures per line. d) Quantification of SHANK3 synaptic content in neurons derived from control (1869 and PB12) or SHANK3 mutated lines. Data are reported as the density of spots per 100 μm of neurite. Results represent mean ± SD of 4 independent neuronal cultures per line. e) Representative images of the neuronal density (NeuN positive cells) and of the neuritic network revealed using beta-III tubulin staining (Tuj-1 antibodies) in control and SHANK3 neuronal cultures. Scale bar = 50 μm. f) Representative images of the v-Gluts (mixed antibodies recognizing v-Glut1 and vGlut-2) staining in control and SHANK3 neuronal cultures. Scale bar = 100 μm. g) Representative images of SHANK3 spots on neurite of control and SHANK3 neurons. Scale bar = 20 μm. h) Quantification of spontaneous calcium oscillation frequency (spike/min) and intensity (F.A.U: Fluorescence Arbitrary Units), reflecting neuronal network activity, in control (PB12 and 1869) and in SHANK3 mutated (SHANK3-STOP and SHANK3 frame-shift) in 42 days-old neuronal culture. Results represent mean ± SD of recording of at least 6 neuronal cultures per lines. In panel c, d and h, values above the two dark grey bars represent the mean ± SD of the two control lines. \*: *p* \< 0.05, control lines vs the indicated SHANK3 mutated line. i) Representative recording of calcium oscillations in control and SHANK3 neuronal cultures.](gr5){#f0025}

![VPA and Lithium treatment efficiency in neurons with SHANK3 mutations.\
a) Quantification of the number of neurite branching points of neurons derived from SHANK3 mutated lines after lithium and VPA treatments. Results represent mean ± SD of 3 independent differentiation/treatment. b) Quantification of SHANK3 synaptic content in neurons derived from iPSC individuals bearing the two different SHANK3 mutations (SHANK3-STOP and SHANK3 frame shift) after 120 h treatment with valproic acid (VPA) or lithium. Results are presented as fold change variations compared to DMSO-treated cells and represented as mean ± SD of at least 6 independent biological replicates/treatment. c) Quantification of spontaneous calcium oscillation frequency and intensity in SHANK3 mutated lines (SHANK3-STOP and SHANK3 frame-shift) with or without treatment with VPA or lithium. Data represent mean ± SD of 4 independent neuronal cultures per treatment. \* *p* \< 0.01 Lithium or VPA vs DMSO. d) Representative images of SHANK3 and Synapsin expression in DMSO, VPA and Lithium treated neurons. e) Representative recording of calcium oscillations.](gr6){#f0030}

![Clinical assessment of patient AUN-003 (SHANK3-STOP).\
T0: Patient AUN-003 aged 12 years old, was enrolled in the study (2012). Black arrow: she developed symptoms of mood deregulation and regression. Red Arrow: start of lithium treatment (0.6 mL--1000 mg/d). T1: 8 months follow-up, T2: one year follow-up. SRS: Social Responsiveness Scale, ADOS: Autism Diagnosis Observational Scale, RPM: Raven\'s progressive matrices, PPVT: Peabody Picture Vocabulary Test, GAS: Global Assessment Scale, ADHD-RS: Attention deficit associated to hyperactivity disorder rating Scale, Y-MRS: Young-Mania rating Scale. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr7){#f0035}
